Supplementary Figure S4 exemplarily shows CD45 immunostaining. For CD45+ lymphocytes at the tumor border, Image J-supported subgroup-analysis revealed a significant increase after Gemcitabine treatment (compared to controls). The gene discussed is PTPRC; the disease is neoplasm.